We are live on ! Find out more
SSC

Spruce Street Capital Portfolio holdings

AUM $510M
This Fund
S&P 500
This Quarter Est. Return
+28.8%
1 Year Est. Return
–
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$510M
AUM Growth
+$93.7M
Cap. Flow
+$9.18M
Cap. Flow %
1.8%
Top 10 Hldgs %
70.24%
Holding
33
New
5
Increased
8
Reduced
1
Closed
3

Top Buys

Rank Stock Value
1
IFRX icon
InflaRx
IFRX
+$10.1M
2
ALKS icon
Alkermes
ALKS
+$8.82M
3
KNSA icon
Kiniksa Pharmaceuticals
KNSA
+$8.14M
4
ZLAB icon
Zai Lab
ZLAB
+$5.51M
5
RACC
Research Alliance Corp III
RACC
+$5.21M

Top Sells

Rank Stock Value
1
CNTA
Centessa Pharmaceuticals
CNTA
+$19.5M
2
KALV
KalVista Pharmaceuticals
KALV
+$18.1M
3
MAZE
Maze Therapeutics
MAZE
+$5.97M
4
DNTH icon
Dianthus Therapeutics
DNTH
+$1.61M

Sector Composition

Rank Sector Weight
1 Healthcare 97.55%
2 Financials 2.45%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
KNSA icon
1
Kiniksa Pharmaceuticals
KNSA
$6.19B
$58.7M 11.52%
918,070
+157,007
+21% +$8.14M
RLAY icon
2
Relay Therapeutics
RLAY
$4.33B
$55.8M 10.95%
2,984,125
– –
LBRX
3
LB Pharmaceuticals
LBRX
$1.56B
$44.7M 8.76%
1,376,159
– –
RLMD icon
4
Relmada Therapeutics
RLMD
$489M
$44.2M 8.68%
6,391,328
+129,214
+2% +$903K
ANRO icon
5
Alto Neuroscience
ANRO
$1.42B
$35.7M 7.01%
1,353,047
+27,837
+2% +$644K
DNTH icon
6
Dianthus Therapeutics
DNTH
$6.16B
$34.6M 6.79%
354,816
-18,458
-5% -$1.61M
ALKS icon
7
Alkermes
ALKS
$8.2B
$28.5M 5.59%
543,876
+225,884
+71% +$8.82M
SVRA icon
8
Savara
SVRA
$1.14B
$21.3M 4.17%
3,452,576
+69,401
+2% +$372K
PCVX icon
9
Vaxcyte
PCVX
$9.21B
$17.8M 3.49%
306,047
+60,338
+25% +$3.28M
ELVN icon
10
Enliven Therapeutics
ELVN
$4.48B
$16.7M 3.28%
329,006
– –
ENTA icon
11
Enanta Pharmaceuticals
ENTA
$411M
$15.9M 3.11%
1,088,731
+156,133
+17% +$2.1M
CATX icon
12
Perspective Therapeutics
CATX
$364M
$12.6M 2.47%
3,693,931
+1,066,824
+41% +$4.03M
IFRX icon
13
InflaRx
IFRX
$302M
$12M 2.35%
+5,352,198
New +$10.1M
SRZN icon
14
Surrozen
SRZN
$282M
$11.2M 2.2%
432,040
– –
ALMS
15
Alumis Inc
ALMS
$2.98B
$11M 2.17%
392,574
– –
IPSC icon
16
Century Therapeutics
IPSC
$384M
$9.94M 1.95%
4,059,054
– –
NERV icon
17
Minerva Neurosciences
NERV
$230M
$9.19M 1.8%
1,655,500
– –
SABS icon
18
SAB Biotherapeutics
SABS
$329M
$8.57M 1.68%
2,198,502
– –
ANTX icon
19
AN2 Therapeutics
ANTX
$212M
$8.04M 1.58%
1,661,073
– –
ERAS icon
20
Erasca
ERAS
$6.16B
$7.74M 1.52%
422,543
– –
IKT icon
21
Inhibikase Therapeutics
IKT
$349M
$7.27M 1.43%
3,581,603
– –
RACC
22
Research Alliance Corp III
RACC
$192M
$5.35M 1.05%
+500,000
New +$5.21M
HLXC
23
Helix Acquisition Corp III
HLXC
$241M
$5.32M 1.04%
500,000
– –
ZLAB icon
24
Zai Lab
ZLAB
$2.88B
$5.3M 1.04%
+279,110
New +$5.51M
ACHV icon
25
Achieve Life Sciences
ACHV
$817M
$4.81M 0.94%
+736,637
New +$3.51M
1
2

Similar funds

TCM
Towneley Capital Management Laguna Hills, California $509M AUM 17.24% 1-Year Est. Return
CRWM
Castle Rock Wealth Management Walnut Creek, California $509M AUM 36.93% 1-Year Est. Return
AG
Alibaba Group Causeway Bay, Hong Kong $509M AUM 25.62% 1-Year Est. Return
TGY2IT
Timothy G. Youngquist 2020 Irrevocable Trust Fort Myers, Florida $510M AUM
AWM
Aries Wealth Management Portland, Maine $509M AUM 25.6% 1-Year Est. Return
RPSA
Richard P. Slaughter Associates Austin, Texas $510M AUM 21.97% 1-Year Est. Return
WCP
Welch Capital Partners Harrison, New York $510M AUM 23.67% 1-Year Est. Return
MPPLM
Midwest Professional Planners Ltd (MPPL) Wausau, Wisconsin $510M AUM 49.02% 1-Year Est. Return

Spruce Street Capital's Q2 2026 Portfolio in Review

As of Q2 2026, Spruce Street Capital held 33 positions worth $510M, up 23% from $416M the previous quarter. Its ten largest holdings account for 70% of the portfolio.

Spruce Street Capital's Q2 2026 filing shows 5 new, 8 increased, 1 reduced and 3 closed positions. Its largest new stake was InflaRx: 5,352,198 shares worth $12M. The largest sale was Centessa Pharmaceuticals, an estimated $19.5M.

By sector, the portfolio is most concentrated in Healthcare at 98% of assets, down from 99% a quarter earlier, followed by Financials.

  • Spruce Street Capital's largest Q2 2026 buy was InflaRx: 5,352,198 shares worth $12M.
  • Spruce Street Capital added most to Alkermes in Q2 2026, an estimated $8.82M increase.
  • Spruce Street Capital's biggest Q2 2026 reduction was Dianthus Therapeutics, cutting an estimated $1.61M.
  • Spruce Street Capital fully exited Centessa Pharmaceuticals in Q2 2026, selling an estimated $19.5M.
  • Spruce Street Capital's ten largest holdings make up 70% of its $510M portfolio in Q2 2026.
  • Spruce Street Capital opened 5 new positions and closed 3 in Q2 2026.
  • Spruce Street Capital's portfolio value rose 23% quarter-over-quarter to $510M.

Based on Spruce Street Capital's 13F filing for Q2 2026, filed 13 Aug 2026.